Actavis remains on acquisition tour
Hafnarfjordur - Actavis Group, an international generic pharmaceuticals company operating from Iceland, has acquired Sindan, a Romanian manufacturer of generic anticancers , for around Euro147.5 million to put its first step into the oncology business. Sindan has a portfolio of 31 own products and markets more than 70 drugs for other companies in Romania. Meanwhile, Actavis' bid for the Croatian generic pharmaceutical company Pliva has not yet met with success. Lastly, Actavis has raised its offer up to Euro81 per share and CEO Robert Wessman has visited Pliva. But, so far, Pliva continues to insist that the offered price still does not reflect its real value.